Solvonis Therapeutics's total assets for Q4 2024 were £3.20M, an increase of 49.74% from the previous quarter. GB:SVNS total liabilities were £119.00K for the fiscal quarter, a -75.41% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.